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Abstract
Background: Whole body genetic deletion of AT1a receptors in mice uniformly reduces hypercholesterolemia and
angiotensin II-(AngII) induced atherosclerosis and abdominal aortic aneurysms (AAAs). However, the role of AT1a receptor
stimulation of principal cell types resident in the arterial wall remains undefined. Therefore, the aim of this study was to
determine whether deletion of AT1a receptors in either endothelial cells or smooth muscle cells influences the development
of atherosclerosis and AAAs.
Methodology/Principal Findings: AT1a receptor floxed mice were developed in an LDL receptor 2/2 background. To
generate endothelial or smooth muscle cell specific deficiency, AT1a receptor floxed mice were bred with mice expressing
Cre under the control of either Tie2 or SM22, respectively. Groups of males and females were fed a saturated fat-enriched
diet for 3 months to determine effects on atherosclerosis. Deletion of AT1a receptors in either endothelial or smooth muscle
cells had no discernible effect on the size of atherosclerotic lesions. We also determined the effect of cell-specific AT1a
receptor deficiency on atherosclerosis and AAAs using male mice fed a saturated fat-enriched diet and infused with AngII
(1,000 ng/kg/min). Again, deletion of AT1a receptors in either endothelial or smooth muscle cells had no discernible effects
on either AngII-induced atherosclerotic lesions or AAAs.
Conclusions: Although previous studies have demonstrated whole body AT1a receptor deficiency diminishes
atherosclerosis and AAAs, depletion of AT1a receptors in either endothelial or smooth muscle cells did not affect either
of these vascular pathologies.
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Introduction
There is substantial and consistent literature demonstrating that
manipulation of the renin angiotensin system has profound effects
on experimental atherosclerosis and abdominal aortic aneurysms
(AAAs). All these effects of the renin angiotensin system are
assumed to be mediated via the major bioactive peptide of this
system, angiotensin II (AngII). For atherosclerosis, pharmacolog-
ical inhibition of AngII synthesis, through inhibition of ACE or
renin, reduced the size of atherosclerotic lesions in several
experimental models of atherosclerosis. For example, ACE
inhibitors reduced atherosclerotic lesion size in mice, hamsters,
rabbits, and monkeys [1–4]. Renin inhibition also markedly
attenuated atherosclerotic lesion size in mouse and rabbit models
[5–7]. Additionally, AngII has been invoked as a mediator of
AAAs based on many studies demonstrating that chronic infusion
of AngII leads to pronounced aortic expansion in hyper- and
normocholesterolemic male mice [8–10].
The majority of the physiological and pathological effects of
AngII are via stimulation of AT1 receptors [11]. Inhibition of AT1
receptors using multiple members of the sartan family of drugs
profoundly reduced atherosclerosis in mouse, rabbit, and monkey
models of the disease [1,12,13]. In mice, chromosomal duplication
has resulted in expression of two isoforms of this receptor, termed
AT1a and AT1b. Although these two receptors are 94% amino
acid homologous and not discriminated by sartans, they have
distinct patterns of distributional and functional characteristics,
with the AT1a isoform being considered as the primary regulator
of most AngII effects. In agreement with pharmacological
inhibition, genetically engineered deletion of AT1a receptors
strikingly reduced atherosclerosis in both apoE 2/2 and LDL
receptor 2/2 mice in multiple studies [14–19]. These major
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effects of AT1a receptor depletion on atherosclerosis occurred
without changes of pronounced hypercholesterolemia. AT1a
receptor stimulation is also a requirement for the development
of AngII-induced AAAs [18,20].
While there is consistent evidence that AT1a receptors regulate
the development of atherosclerotic lesions and AAAs, these effects
may be attributable to stimulation of several cell types. Bone
marrow transplantation has been used as an approach to define
effects of AT1a receptor activation on leukocytes. However,
contrary to the consistently large reductions of atherosclerosis in
mice with whole body deficiency of AT1a receptors, depletion of
this receptor in bone marrow-derived cells has highly variable
effects. This has included a range of influences on lesion size
including no effects in LDL receptor 2/2 and apoE2/2 mice
fed saturated fat enriched diets with or without AngII infusion
[5,18,21], decreases [17,22], and increases [23]. The sole study in
AngII-induced AAAs failed to detect any effect of AT1a receptor
expression in bone marrow-derived cells on development of AAAs
[18]. Hence, it is unclear which cell type is being stimulated by
AngII to promote the development of these two vascular
pathologies.
There are many AngII-induced processes defined in cultured
endothelial and smooth muscle cells, inferring its relevance to
atherogenesis. However, the role of AngII stimulation of specific
cell types in vivo on the development of atherosclerotic lesions and
AAAs has not been directly examined. Therefore, the novelty of
this study was to use our recently developed AT1a receptor floxed
mice to determine the contribution of AT1a receptor stimulation
in either endothelial or smooth muscle cells. Despite validation of
AT1a receptor depletion in these two cell types in vivo, the
absence of this receptor type in either cell type had no discernible
effect on the development of atherosclerosis or AAAs.
Materials and Methods
Ethics Statement
This study followed the recommendations of The Guide for the
Care and Use of Laboratory Animals (National Institutes of
Health). All procedures were approved by the University of
Kentucky’s Institutional Animal Care and Use Committee
(Protocol # 2006–0009). The mice were observed daily for any
signs of distress and weighed weekly to monitor health.
Mice
Agtr1a receptorflox/flox mice were generated by inGenious
Targeting Laboratory using a C57BL/6 embryonic stem cell line
[24]. These mice are now available at The Jackson Laboratory
(C57BL/6N-Agtr1atm1Uky/J; stock # 016211). LDL receptor 2/2
(stock # 2207), SM22-Cre (stock # 4746) and Tie2-Cre (stock #
4128) mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). SM22-Cre mice, initially acquired in a mixed
background, were bred into a C57BL/6 strain and screened using
The Jackson Laboratory’s Speed Congenic Service to expedite the
development of the C57BL/6 background. Mice were bred to
produce the following breeding harems: male Agtr1a receptorflox/
flox x Tie2-Cre or SM22-Cre x LDL receptor 2/2 and female
Agtr1a receptorflox/flox x LDL receptor 2/2 mice.
Atherosclerosis and Aneurysm Studies
For hypercholesterolemia-induced atherosclerosis studies, male
and female mice (8–12 weeks old) were fed a diet enriched in
saturated fat (Diet# TD.88137; Harlan Teklad, Indianapolis, IN)
containing milk fat (21% wt/wt) and cholesterol (0.2% wt/wt) for
12 weeks.
For AngII-induced atherosclerosis and aortic aneurysm studies,
male mice (8 weeks old) were fed the saturated fat enriched diet
listed above for 5 weeks. After 1 week of feeding, mini osmotic
pumps (Model # 2004; Durect Corp, Cupertino, CA) filled with
saline or AngII (1,000 ng/kg/min; Cat # H-1705; Bachem,
Torrance, CA) were implanted subcutaneously in the right flanks
of mice [8,25]. Duration of continuous infusion was 28 days.
Genotyping
Genomic DNA was isolated from mouse tails and genotyped
using PCR as described previously [24]. A representative
electrophoretic gel of the amplicons is shown in Figure S1.
Serum analyses
At termination, blood was collected by cardiac puncture and
serum was separated by centrifugation. Lipoprotein fractions were
resolved by size exclusion chromatography from serum of
individual mice (50 ml) using a size exclusive chromatography
(FPLC) [26]. Eluted fractions and total serum cholesterol were
measured using an enzymatic kit (Cat # Cholesterol E 439-17501;
Wako Chemicals, Richmond, VA).
Systolic Blood Pressure Measurements
Systolic blood pressure was measured on conscious mice using a
noninvasive tail-cuff system (CODA 8; Kent Scientific Corp,
Torrington, CT) as described previously [27]. Systolic blood
pressure was determined by measurements on at least 3
consecutive days at baseline, and during the last week of study.
Atherosclerotic Lesion and AAA Quantification
After exsanguination, aortas were perfused with saline, dissected
free, and fixed in 10% neutral buffered formalin overnight. The
next day, aortas were transferred to saline and adventitia were
removed. For atherosclerotic lesion measurements, aortas were cut
open, pinned, and photographed, and area was measured using
ImagePro Plus software [28,29]. Measurement of aortic lumen
diameter was performed using a Visualsonics Vevo 660 high
frequency ultrasound machine as described previously [30]. For
aneurysm quantification, external diameter of suprarenal aortas
was measured using ImagePro Plus software [18,31].
Statistical Analyses
Appropriate analyses were conducted based on group number
compared and parametric characteristics of the data using
SigmaPlot version 12.0 (Systat Software Inc, San Jose, CA). Data
are represented as mean 6 SEM. P,0.05 was considered
statistically significant.
Results
AT1a Receptor Depletion in Endothelial Cells had no
Effect on Hypercholesterolemia-induced Atherosclerosis
To examine the role of endothelial cell AT1a receptors in
atherosclerosis, LDL receptor deficient mice were developed with
floxed AT1a receptor mice that express Cre under the control of
the Tie2 promoter. We have described previously that expression
of Cre under control of the Tie2 promoter leads to profound
reductions in AT1a receptor mRNA in endothelial cells and had
consistent effects on aortic endothelial cells throughout the aorta
[24]. Male and female AT1aRflox/flox x LDL receptor 2/2 mice
that were hemizygous for Cre were compared to littermates that
did not express Cre. Whole body AT1a receptor deficient mice
were also added as a control group. All mice were fed a diet
Cell-Specific AT1aR Depletion in Aortic Pathology
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enriched in saturated fat for 12 weeks. As expected, body weight
was affected by gender as male mice were heavier than females
(P,0.001; Table 1). Total serum cholesterol concentrations and
lipoprotein distribution of cholesterol were similar in all groups
(Table 1 and Figure S2). Consistent with previous publications
[15], percent atherosclerotic lesion area was decreased in LDL
receptor 2/2 mice with whole body deficiency of AT1a
receptors. However, lesion areas were not significantly different
between wild type and endothelial cell specific AT1a receptor
deficient mice in either gender (Figure 1).
AT1a Receptor Depletion in Smooth Muscle Cells had no
Effect on Hypercholesterolemia-induced Atherosclerosis
To examine the role of smooth muscle cell AT1a receptors in
atherosclerosis, LDL receptor deficient mice were developed with
floxed AT1a receptor mice that express Cre under the control of
the SM22 promoter. We have described previously that the
expression of Cre under the control of the SM22 promoter leads to
pronounced reductions in AT1a receptor mRNA in smooth
muscle cells, and has a consistent effect on smooth muscle cells
throughout the aorta [24]. Male and female littermate LDL
receptor 2/2 mice that were wild type or deficient in smooth
muscle cell AT1a receptors were fed the saturated fat-enriched
diet for 12 weeks. Serum total cholesterol concentrations were
increased in males compared to females (male versus female:
1860660 versus 1437654 mg/dl; P,0.001), although distribu-
tions of cholesterol among lipoprotein fractions were similar
between genders (Figure S3). Smooth muscle cell deficiency of
AT1a receptors had no effect on serum cholesterol concentrations
(Table 2). Percent atherosclerotic lesion area was equivalent
between genders, and was not influenced between the genotypes of
AT1a receptors in smooth muscle cells (Figure 2).
AT1a Receptor Depletion in Endothelial Cells had no
Effect on AngII-induced AAAs and Atherosclerosis
To examine the role of endothelial cell AT1a receptors in
AngII-induced AAAs and atherosclerosis, male littermate LDL
receptor 2/2 mice, that were wild type or deficient in endothelial
cell AT1a receptors, were fed a saturated fat enriched diet and
infused with either saline or AngII (1,000 ng/kg/min) for 28 days.
Genotype or AngII infusion had no effect on body weight and
serum cholesterol concentrations (Table 3). Systolic blood pressure
was not different between the saline-infused mice. AngII infusion
at 1,000 ng/kg/min significantly increased systolic blood pressure
in both genotypes (P,0.05; Table 3). Diameters of abdominal
aortas were measured both in vivo by ultrasound and ex vivo. AngII
Figure 1. Endothelial depletion of AT1a receptors had no
effects on atherosclerotic lesion area. Individual measurements
are represented from littermates that were either male (circles) or
female (inverted triangles). Blue symbols are non-transgenic, pink
symbols are Tie2-Cre +/0, and teal symbols are whole body AT1aR
deficient mice. Diamond symbols are group means and bars are
standard error of means (0/0 = non-transgenic littermate; +/0 = Tie2-
Cre hemizygous transgenic; 2/2 = AT1a receptor 2/2). * denotes
P,0.05 when comparing 2/2 to 0/0 or +/0 within either gender.
doi:10.1371/journal.pone.0051483.g001
Table 1. Body weight and serum cholesterol concentration of
LDL receptor 2/2 mice that were Tie2-Cre 0/0, Tie2-Cre +/0,
or AT1a receptor 2/2.
Genotype Gender n Body weight (g)
Cholesterol (mg/
dl)
Tie2-Cre 0/0 Male 20 46.761.4 1676663
Tie2-Cre +/0 20 43.361.1 1677695
2/2 7 36.562.8* 16796118
Tie2-Cre 0/0 Female 15 34.061.5* 1545671
Tie2-Cre +/0 29 34.661.1* 1676659
2/2 5 27.361.8* 14206204
Body weight and serum cholesterol concentration were measured at
experimental termination. There were no differences in measurements between
Tie2 0/0 or +/0 attained statistical significance.
*denotes P,0.05 compared to male within genotype (0/0 = no Cre; +/0 =
hemizygous Cre; 2/2 = whole body deficiency of AT1a receptor).
doi:10.1371/journal.pone.0051483.t001
Figure 2. Smooth muscle cell depletion of AT1a receptors had
no effects on atherosclerotic lesion area. Individual measurements
are represented from littermates that were either male (circles) or
female (inverted triangles). Blue symbols are non-transgenic and pink
symbols are SM22-Cre +/0 mice. Diamond symbols are group means
and bars are standard error of means (0/0 = non-transgenic littermate
and +/0 = SM22-Cre hemizygous transgenic).
doi:10.1371/journal.pone.0051483.g002
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infusion significantly increased lumen diameter of abdominal
aortas (P,0.001; Figure 3A) and ex vivo aortic width (P = 0.004;
Figure 3B) in both genotypes. There were no differences between
genotypes (P = 0.995 and P = 0.717, respectively). AngII infusion
significantly increased atherosclerosis in both genotypes when
compared to saline infusion (P,0.001; Figure 4), whereas
endothelial specific AT1a receptor deficiency did not exert any
significant effect (P = 0.479).
AT1a Receptor Depletion in Smooth Muscle Cells had no
Effect on AngII-induced AAAs and Atherosclerosis
To examine the role of smooth muscle cell AT1a receptors in
AngII-induced AAAs and atherosclerosis, male littermate LDL
receptor 2/2 mice that were wild type or deficient for smooth
muscle cell AT1a receptors, were fed a saturated fat-enriched diet
and infused with either saline or AngII (1,000 ng/kg/min) for 28
days. Genotype or AngII infusion had no effect on body weight
and serum cholesterol concentrations (Table 3). Systolic blood
pressure was not different between the saline-infused mice. AngII
infusion significantly elevated systolic blood pressure in both
genotypes (P,0.05; Table 3). Abdominal aortas were scanned by
ultrasound at baseline, day 0 and again at day 28 of infusion.
AngII infusion significantly increased lumen diameter of abdom-
inal aortas (P,0.001; Figure 5A) and ex vivo aortic width
(P = 0.004; Figure 5B) in both genotypes. There were no
differences between genotypes (P = 0.665 and P = 0.725, respec-
tively). AngII infusion significantly increased atherosclerosis in
both genotypes when compared to saline infusion (P,0.001;
Figure 6), but similar to endothelial cell-specific deficiency, smooth
muscle cell-specific AT1a receptor genotypes did not exert any
significant effect (P = 0.459).
Discussion
Inhibition of AT1 receptor stimulation through pharmacolog-
ical antagonism or genetic manipulations has been a highly
consistent mode of decreasing experimental atherosclerosis in
many animal models [32]. These pronounced reductions in
atherosclerotic lesion size have occurred in the absence of any
discernible effect on hypercholesterolemia, which is considered a
pivotal determinant of atherosclerosis [14,15]. In agreement with
this literature, the present study confirmed that effects of whole
body depletion of AT1a receptors profoundly inhibited athero-
sclerotic formation in both genders. Inhibition of AT1 receptors
also ablates the development of AngII-induced AAAs. Since
endothelial and smooth muscle cells are the major resident cell
types in the arterial regions of atherosclerosis and AAAs, we
proposed that depletion of AT1a receptors in either of these two
cell types would reduce the development of these vascular
pathologies. Using AT1a receptor floxed mice with previously
validated approaches to deleting AT1a receptor expression in
endothelial or smooth muscle cells, we were surprised that deletion
of this receptor in either of the two resident cell types had no
significant effects on atherosclerosis and AAAs.
Although the effects of AT1a receptor expression on cell types
resident in the arterial wall have not been determined previously,
several studies have focussed on the role of AT1a receptor
expression in leukocytes in the development of atherosclerosis in
hypercholesterolemic mice, including some studies with AngI
infusion. The abundance of leukocytes in experimental athero-
sclerotic lesions provides a basis for a focus on this group of cell
types. The studies have used the technique of repopulating
irradiated mice with bone marrow-derived cells that are either
wild type or deficient in AT1a receptors. These studies have
generated highly variable results that cover the spectrum of
inhibiting, having no effect, or promoting atherosclerosis
Table 2. Body weight and serum cholesterol concentration of
LDL receptor 2/2 mice that were SM22-Cre 0/0 or +/0.
Cre genotype Gender n Body weight (g)
Cholesterol (mg/
dl)
SM22-Cre 0/0 Male 23 44.860.9 1943699
SM22-Cre +/0 15 44.761.4 1777694
SM22-Cre 0/0 Female 23 32.361.2* 1519681*
SM22-Cre +/0 23 32.461.0* 1355659*
Body weight and serum cholesterol concentration were measured at
experimental termination. There were no significance differences in these
measurements between SM22 0/0 or +/0 attained statistical significance.
*denotes P,0.05 compared to male within genotype (0/0 = no Cre; +/0 =
hemizygous Cre).
doi:10.1371/journal.pone.0051483.t002
Figure 3. Endothelial depletion of AT1a receptors had no
effects on AngII-induced abdominal aortic dilation measured
in vivo by ultrasonography or ex vivo. A. Measurements of lumen
diameters of suprarenal aortas by high frequent ultrasound on day 0
and day 28 of AngII infusion. B. Measurements of maximal external
diameter of suprarenal aortas on ex vivo tissues acquired at termination.
Individual measurements are represented from littermates that were
either non-transgenic (circles) or Tie2-Cre +/0 (inverted triangles)
infused with saline (left) or AngII (right). Diamond symbols are group
means and bars are standard error of means (0/0 = non-transgenic
littermates and +/0 = Tie2-Cre hemizygous transgenic). * denotes
P,0.05 when comparing saline versus AngII-infused mice.
doi:10.1371/journal.pone.0051483.g003
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[5,17,18,21–23]. We have been unable to distinguish the basis for
these highly variable findings. Only one study reported the effects
of leukocyte AT1a receptors on AAAs, which failed to demon-
strate an effect of AT1a receptors in bone marrow-derived cells on
the formation of AAAs [18]. It has been documented that the
process of bone marrow transplantation may influence athero-
sclerosis and AAA formation in mice [18,33]. Therefore, future
studies on the role of AT1a receptor expression in leukocytes may
be benefited from the application of Cre-lox approaches as
performed on the cell types that were the focus of the present
study.
Chronic subcutaneous infusion of AngII into hyper- or
normocholesterolemic mice has been used in numerous studies
to generate AAAs [8,25,34]. The pivotal role of AT1a receptors
has been demonstrated by the ablation of AAAs in whole body
AT1a receptor deficient mice [18]. Although leukocyte infiltration
is a prominent feature of AngII-induced AAAs [35], deficiency of
AT1a receptors in this cell type had no effect on the extent of
aortic dilation [18]. Endothelial and smooth muscle cells are other
potential cell types stimulated by AngII in the evolution of
aneurysmal diseases. However, similar to atherosclerosis, deletion
Figure 4. Endothelial depletion of AT1a receptors had no
effects on AngII-induced atherosclerosis. Individual measure-
ments are represented from littermates that were either non-transgenic
(circles) or Tie2-Cre +/0 (inverted triangles) infused with saline (left) or
AngII (right). Diamond symbols are group means and bars are standard
error of means (0/0 = non-transgenic littermate and +/0 = Tie2-Cre
hemizygous transgenic). * denotes P,0.05 comparing saline versus
AngII infused mice.
doi:10.1371/journal.pone.0051483.g004
Table 3. Body weight, serum cholesterol concentration, and systolic blood pressure of LDL receptor 2/2 mice with deletion of
AT1a receptors in endothelial (Tie2-Cre +/0) or smooth muscle cells (SM22-Cre +/0).
Cre genotype Infusion n Body weight (g) Cholesterol (mg/dl) SBP (mmHg)
0/0 Saline 5 30.060.6 1308641 14665
AngII 18 30.460.8 1254659 17364*
Tie2-Cre +/0 Saline 4 28.861.0 12696193 144610
AngII 15 29.461.1 1305662 17466*
SM22-Cre +/0 Saline 6 29.661.6 1269679 136610
AngII 25 29.060.6 1561660 15264*
Body weight and serum cholesterol concentration were measured at experimental termination. Systolic blood pressure (SBP) was measured daily for at least 3
consecutive days during the final week of AngII infusion.
*denotes P,0.05 compared to saline within genotype (0/0 = no Cre; +/0 = hemizygous Cre).
doi:10.1371/journal.pone.0051483.t003
Figure 5. Smooth muscle cell depletion of AT1a receptors had
no effects on AngII induced abdominal aortic dilation mea-
sured in vivo by ultrasonography or ex vivo. A. Individual
measurements of lumen diameter of suprarenal aortas by high
frequently ultrasound on day 0 and day 28 of AngII infusion. B.
Individual measurements of maximal external diameter of suprarenal
aortas on ex vivo tissue acquired a termination. Measurements are
represented from littermates that were either non-transgenic (circles) or
SM22-Cre +/0 (inverted triangles) infused with saline (left) or AngII
(right). Diamond symbols are group mean and bars are standard error
of mean (0/0 = non-transgenic littermates and +/0 = SM22-Cre
hemizygous transgenic). * denotes P,0.05 comparing saline versus
AngII-infused mice.
doi:10.1371/journal.pone.0051483.g005
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of AT1a receptors in either endothelial or smooth muscle cells had
no effect on the development of AAAs.
One potential explanation for the lack of effects of AT1a
receptor depletion in either endothelial or smooth muscle cells on
atherosclerosis and AAAs would be limited excision of the exon 3
of the AT1a receptor gene in Cre expressing floxed mice. Using
lineage tracking, we have demonstrated previously the uniformity
of the AT1a receptor gene deletion in smooth muscle and
endothelial cells using SM22 and Tie2 promoters, respectively, to
drive Cre expression [24]. Furthermore, we have demonstrated
previously that Cre driven by these promoters leads to ablation of
AT1a receptor mRNA abundance in these respective cell types
[24]. It would be desirable to have performed immunostaining of
AT1a receptors to demonstrate deletion in these two cell types.
Unfortunately, following validation with control experiments, we
have been unable to demonstrate specific staining for AT1a
receptors using a number of antibodies, [24,36,37]. The difficulty
of detecting AT1a receptors in mice is compounded by the close
structural similarities of AT1b receptors that are highly expressed
in aortic tissues [38]. A potential confounding issue in the use of
the Tie2 promoter is that, in addition to effects on endothelial
cells, there is also deletion of genes in myeloid cells due to common
precursor cells. However, this does not appear to impact the
present study based on the previous demonstration that deletion of
AT1a receptor in bone marrow-derived cells had no effect on
atherosclerosis and AAAs [5,18].
Endothelial cells are the initial barrier for entry of biochemical
or cellular mediators of atherosclerosis in vivo. AngII exerts effects
on endothelial cells in vitro that may potentially promote
atherosclerosis, including increased expression of VCAM-1 [39];
however, this has not been consistently observed [5,40]. Also,
there are several reports of AngII promoting leukocyte adhesion to
cultured endothelial cells [5,40,41]. Despite strong evidence from
in vitro studies that AngII stimulation of endothelial cells is pro-
atherogenic, endothelial specific depletion of AT1a receptors had
no effects on the development of atherosclerosis in both genders of
LDL receptor 2/2 mice.
The endothelium has a less defined role in the development of
AAAs compared to atherosclerosis. We have demonstrated
recently that endothelial-specific deletion of AT1a receptors
partially attenuates the development of AngII-induced thoracic
aortic aneurysms [24]. However, the pathology of AngII-induced
aortic aneurysms in the ascending aorta differs markedly from
those formed in the abdominal aorta [42]. Indeed it has been
proposed that AngII-induced AAAs involve adventitial mecha-
nisms [43,44]. This proposal would be consistent with AngII not
exerting effects on endothelium in AAA formation.
Smooth muscle cells are one of the prominent components of
human atherosclerotic lesions [45,46]. This cell type is a more
sparse contributor to the cellularity of lesions in hypercholester-
olemic mice, such as LDL receptor 2/2 and apoE 2/2 mice
[47,48]. Nevertheless, genetic deletion of some molecules in
smooth muscle cells has been shown to influence the development
of atherosclerosis in these hypercholesterolemic mouse models.
These include deletions of peroxisome proliferator-activated
receptor gamma [49], cGMP-dependent protein kinase [50],
and low density lipoprotein related protein [51]. Even in the
absence of substantial numbers of smooth muscle cells within
lesions, there is also possible that AngII stimulation of this cell type
in the media could influence lesion formation in the intima. For
example, AngII incubation with cultured smooth muscle cells
induces expression of MCP-1 [52]. Deficiency of MCP-1 reduces
atherosclerotic development, although the in vivo cellular sources
of this cytokine in promoting lesion formation has not been
defined [53]. Our results demonstrate that depletion of AT1a
receptors in this cell type had no discernible effect on atheroscle-
rosis in both males and females. Smooth muscle cell-specific
deletion of AT1a receptors also had no effect on systolic blood
pressure in the presence or absence of AngII infusion, which is
consistent with previous reports [24,54]. The SM22 promoter used
to drive Cre synthesis in this study has some vascular regional-
specific expression. There is low expression in renal vasculature,
the major arterial bed regulating AngII-induced increases in blood
pressure [54]. Therefore, the equivalent AngII-induced increases
in blood pressure in SM22-Cre expressing and non transgenic
littermates are likely due to lack of deletion in pressor vascular
beds. In agreement, recent studies demonstrated that AngII-
induced elevations in blood pressure are reduced by removal of
AT1a receptors from renal proximal tubule cells [55,56].
AngII-induced AAAs are characterized by local disruption
within smooth muscle cells of the media [35]. Therefore, we
anticipated a profound role for smooth muscle cell-specific
deletion of AT1a receptors in vascular pathology. In a recent
study, we were able to detect a partial role of AT1a receptor
depletion in smooth muscle cells on AngII-induced AAAs in
neonatal female mice that were transiently exposed to testosterone
and then infused with the peptide as adults [34]. In the present
study, male mice were studied since this gender has a greater
propensity to develop AngII-induced AAAs [57,58]. We were
unable to discern any effect of smooth muscle cell-specific
depletion of AT1a receptors in large groups of adult male mice
for AngII-induced AAAs. Despite lack of defining a direct effect of
AngII on smooth muscle cells, there has been evidence of a
pronounced role of adventitial fibroblasts in the development of
AngII-induced aorta pathologies [44]. Therefore, future experi-
ments examining the cellular basis of AngII-induced AAAs will
involve this cell type.
In conclusion, the current study has used recently developed
and validated AT1a receptor floxed mice to determine the effects
of AT1a receptors in endothelial or smooth muscle cells on the
development of atherosclerosis and AAAs in LDL receptor 2/2
Figure 6. Smooth muscle cell depletion of AT1a receptors had
no effects on AngII-induced atherosclerosis. Individual measure-
ments are represented from littermates that were either non-transgenic
(circles) or SM22-Cre +/0 (inverted triangles) infused with saline (left) or
AngII (right). Diamond symbols are group means and bars are standard
error of means (0/0 = non-transgenic littermate and +/0 = SM22-Cre
hemizygous transgenic). * denotes P,0.05 comparing saline versus
AngII-infused mice.
doi:10.1371/journal.pone.0051483.g006
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mice. Although whole body deletion of this receptor in these mice
caused pronounced decreases in atherosclerosis and AAAs [15,18],
deletion of AT1a receptors in either endothelial or smooth muscle
cells had no discernible effect on atherosclerotic lesion size or AAA
formation.
Supporting Information
Figure S1 Genotyping of experimental mice for AT1a
receptor floxed allele and Cre transgene by PCR.
Genomic DNA from tail biopsies was isolated and screened by
PCR for: (A) wild type and floxed AT1a receptor alleles and, (B)
Cre transgene using IL-2 gene are control. Reaction products were
sized using agarose gel electrophoresis. The primer sets and
predicted product size are listed below.
(TIF)
Figure S2 Depletion of AT1a receptors in endothelial
cells had no effects on lipoprotein distribution of
cholesterol. Serum (50 ml) from individual mice (n = 324/
group; A = males; B = females) was resolved by size exclusion
chromatography. Symbols are group means and bars are standard
error of the means.
(TIF)
Figure S3 Depletion of AT1a receptors in smooth
muscle cells had no effects on lipoprotein distribution
of cholesterol. Serum (50 ml) from individual mice (n = 324/
group; A = males; B = females) was resolved by size exclusion
chromatography. Symbols are group means and bars are standard
error of the means.
(TIF)
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